BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
Open original source
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
Open original source